Clinical Report: Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases

Overview

This systematic review and meta-analysis evaluates the survival outcomes of breast cancer patients with spinal metastases based on immunohistochemistry subtypes. It highlights significant survival disparities among subtypes, emphasizing the importance of accurate prognostic stratification in clinical decision-making.

Background

Breast cancer is characterized by genetic and clinical heterogeneity, classified into immunohistochemistry-based subtypes that guide prognosis and therapy. Understanding these subtypes is crucial, particularly in metastatic cases, where survival outcomes can vary significantly. This review addresses the knowledge gap regarding survival outcomes in breast cancer patients with spinal metastases, a common site for metastatic involvement.

Data Highlights

No specific numerical data provided in the article.

Key Findings

• HR + subtype has the highest median survival (26.4 months), while TNBC has the lowest (6.0 months).
• Immunohistochemistry profiling may surpass traditional prognostic systems in predicting survival.
• Spinal metastases account for 18.5% of surgically treated cases of breast cancer.
• Current literature lacks comprehensive survival data for breast cancer with spinal metastases.
• Emerging evidence suggests significant survival differences based on immunohistochemistry subtypes.

Clinical Implications

Clinicians should utilize immunohistochemistry subtyping to inform treatment decisions and prognostic assessments in breast cancer patients with spinal metastases. Accurate survival predictions can guide the choice between palliative and more aggressive surgical interventions.

Conclusion

This review underscores the critical role of immunohistochemistry subtypes in predicting survival outcomes for breast cancer patients with spinal metastases, providing a foundation for improved clinical decision-making.

References

1. The influence of immunohistochemistry-based subtypes on overall survival in breast cancer spine metastases: a systematic review and meta-analysis, BMC Medicine, 2026 -- Title
2. Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes, The ASCO Post, 2020 -- Title
3. Association of Pathologic Complete Response With 3-Year Outcomes in I-SPY 2 Trial of Neoadjuvant Therapy for Stage II or III Breast Cancer, The ASCO Post, 2020 -- Title
4. ASTRO clinical guideline on radiation therapy for bone metastases emphasizes patient-centered care, ASTRO, 2024 -- Title
5. Prognostic Significance of Molecular Subtyping in Muscle-Invasive Bladder Cancer and Its Relationship with Variant Histology in a Single-Institution Cystectomy Cohort
6. The ASCO Post — Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes KEY POINTS Related Articles
7. The influence of immunohistochemistry-based subtypes on overall survival in breast cancer spine metastases: a systematic review and meta-analysis | BMC Medicine | Springer Nature Link
8. ASTRO clinical guideline on radiation therapy for bone metastases emphasizes patient-centered care